alogliptin
Sign in to saveAlogliptin, sold under the brand names Nesina and Vipidia, is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in people whose diabetes cannot adequately be controlled with metformin alone.
Article
5 sectionsContents
- Medical uses
- Side effects
- Market access
- References
- External links
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 454952697 | image = Alogliptin.svg | image_class = skin-invert-image | alt =
| pronounce = | tradename = Nesina, VipidiaKazano, Vipidomet (with metformin)Oseni, Incresync (with pioglitazone) | Drugs.com = | MedlinePlus = a613026 | licence_EU = yes | DailyMedID = Alogliptin | licence_US = | pregnancy_AU = B3 | pregnancy_AU_comment = | pregnancy_US = B | pregnancy_US_comment = | pregnancy_category = | routes_of_administration = By mouth | ATC_prefix = A10 | ATC_suffix = BH04
Connections
Categories
BenzonitrilesChemical articles with multiple CAS registry numbersChemical pages without DrugBank identifierChemicals using indexlabelsDipeptidyl peptidase-4 inhibitorsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrug has EMA linkDrugs developed by Takeda Pharmaceutical CompanyDrugs with non-standard legal statusECHA InfoCard ID from Wikidata